Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2014 May;63(5):406–411. doi: 10.1097/FJC.0000000000000061

Figure 3.

Figure 3

IL-15 increases ERK1/2 phosphorylation in cardiomyocytes which can be blocked by wortmannin, a PI3 kinase inhibitor. A. Wortmannin inhibits the beneficial effects of IL-15 on CM survival. Wortmannin (100 nM) was added to cultures of adult cardiac myocytes after 3 h of hypoxia and just prior to treatment with IL-15 (5 ng/ml) at the onset of 22 h of re-oxygenation.

B. Western blot analysis of IL-15 stimulated ERK1/2 phosphorylation in normoxia was 3.3-fold over untreated cardiomyocyte controls. Wortmannin (100 nM) was added 15 min prior to addition of IL-15 (5 ng/ml) for 10 min, which blocked activation of ERK1/2 phosphorylation.

Nx, normoxia: Hx/Rx, hypoxia/re-oxygenation: Con, control: Wort, wortmannin. A: n = 5 per group. *P < 0.05 vs. control and IL-15. B: n = 7 per group. *P < 0.05 vs. IL-15.